Antioxidant Activity and Cytotoxicity Evaluation of New Catechol Hydrazinyl-Thiazole Derivatives as Potential Protectors in Retinal Degenerative Processes.
Article in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Răzvan-Geo AntemieDepartment of Physiology, Faculty of Medicine, "Iuliu Haţieganu" University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania.ORCID 0000-0002-8739-3155
Gabriel MarcDepartment of Organic Chemistry, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.ORCID 0000-0001-9397-0388
Raluca PeleDepartment of Pharmaceutical Chemistry, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.ORCID 0000-0002-6807-5135
Ionel FizeșanDepartment of Toxicology, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8 Victor Babeș, 400012 Cluj-Napoca, Romania.
Ionuț-Valentin CreștinDepartment of Toxicology, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8 Victor Babeș, 400012 Cluj-Napoca, Romania.ORCID 0009-0003-7144-0847
Raluca BorlanNanobiophotonics and Laser Microspectroscopy Centre, Interdisciplinary Research Institute in Bio-Nano-Sciences, Babeș-Bolyai University, 400084 Cluj-Napoca, Romania.
Panagiotis Theodosis-NobelosDepartment of Pharmacy, School of Health Sciences, Frederick University, Nicosia 1036, Cyprus.
Eleni A RekkaDepartment of Pharmaceutical Chemistry, School of Pharmacy, Aristotelian University of Thessaloniki, 54124 Thessaloniki, Greece.
Ovidiu OnigaDepartment of Pharmaceutical Chemistry, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Ovidiu CrișanDepartment of Organic Chemistry, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Adrian PîrnăuNational Institute for Research and Development of Isotopic and Molecular Technologies, 67-103 Donath Street, 400293 Cluj-Napoca, Romania.ORCID 0000-0002-2313-9350
Laurian VlaseDepartment of Pharmaceutical Technology and Biopharmaceutics, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.ORCID 0000-0002-0664-3387
Simona Valeria ClichiciDepartment of Physiology, Faculty of Medicine, "Iuliu Haţieganu" University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania.ORCID 0000-0002-0046-0803
Funding
"Iuliu Haţieganu" University of Medicine and Pharmacy Cluj-Napoca, Romania PCD 881/3/12 January 2022 and PCD 772/1/11 January 2023"Nucleu" Program within the National Research Development and Innovation Plan 2022-2027, Romania, carried out with the support of MEC 27N/03.01.2023, component project code PN 23 24 01 05Romanian Ministry of Education and Research Installations and Special Objectives of National Interest (IOSIN), IZOSTAB
6 · The paper itself
Abstract
Retinal degenerative processes such as age-related macular degeneration are at the center of many ongoing research studies, as their impact on the general population is significant, with severe visual impairment and even irreversible vision loss if left untreated. Currently, there are few efficient treatments available to stop or limit its progression. In the present paper, a molecular hybridization approach was employed to develop novel compounds that address this issue. By adding either 2-butenal or a β-ionone-derived residue to the hydrazone-catechol-thiazole scaffold, two compounds were designed and synthesized:
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Antioxidant Activity and Cytotoxicity Evaluation of New Catechol Hydrazinyl-Thiazole Derivatives as Potential Protectors in Retinal Degenerative Processes. · full record | Socratic